On the other hand, significant progress has been made in achieving HBsAg loss with Peg-IFN-α therapy, the persistence of HBV in the organism after HBsAg loss in chronic hepatitis B infection remains a concern (Shi & Zheng, 2020; Song et al., 2021). The gene discussed is IFNA1; the disease is chronic hepatitis B virus infection.